<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03977064</url>
  </required_header>
  <id_info>
    <org_study_id>EK205/16</org_study_id>
    <nct_id>NCT03977064</nct_id>
  </id_info>
  <brief_title>Fertility and Cardiovascular Risk in Men With Metabolic Syndrome</brief_title>
  <official_title>Fertility and Cardiovascular Risk in Men With Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Giessen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Giessen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Men diagnosed with metabolic syndrome (MetS) consisting of obesity, hypertension,
      dyslipidemia and infertility will be assessed for cardiovascular and diabetes risk. The
      eligible patient will be randomised to one-year life-style intervention program including
      nutritional, behavioural and exercise counselling or standard care by the general physician.
      The aim of the program is to reduce cardiovascular and diabetes risks and hypogonadism as
      well.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The outcomes assessor will receive pseudonymized data</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with normalisation of diabetes or cardiovascular risk or improvement of hypogonadism</measure>
    <time_frame>1 year</time_frame>
    <description>Diabetes risk Glycated hemoglobin &gt;5.7%, Cardiovascular risk: PROCAM score &gt;5%, Hypogonadism score increase of 20 points</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Intensive treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intensive treatment group will pass a life-style intervention program including consequent escalation of measures to reach sustained reduction of 10% of initial body weight at minimum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard treatment group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will be taken care of by general physician without lifestyle program.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Life style change and weight reduction</intervention_name>
    <description>Nutritional, behavioural, and exercise counselling to reduce body weight by 10%, normalise blood glucose, lipids, blood pressure, and testosterone level.</description>
    <arm_group_label>Intensive treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age&gt;18 years, wish for fatherhood in stable partnership, metabolic syndrome according
             to guidelines (minimum 3 out of 5 criteria), ready to participate in 1-yr lifestyle
             program

        Exclusion Criteria:

          -  Not conforming to MetS diagnosis criteria, sterilisation, promiscuous behaviour,
             contraindications against established medical or surgical treatment of obesity,
             participation in another weight-loss program
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Males diagnosed with metabolic syndrome</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thomas Linn, MD</last_name>
    <phone>+49 641 985 57017</phone>
    <email>thomas.linn@innere.med.uni-giessen.de</email>
  </overall_contact>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 4, 2019</study_first_submitted>
  <study_first_submitted_qc>June 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2019</study_first_posted>
  <last_update_submitted>June 4, 2019</last_update_submitted>
  <last_update_submitted_qc>June 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

